Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05916508 · ClinicalTrials.gov registry record · NA

A Bleeding-Model Clinical Study

A NA study, sponsored by Procter and Gamble.

Completed
Registry status
NA
Development phase
90
Enrollment target

NCT05916508: Completed NA study, sponsored by Procter and Gamble.

NCT05916508 is a NA study that has completed, run by Procter and Gamble. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05916508, a NA study, has completed, sponsored by Procter and Gamble.

COMPLETED
Registry status
NA
Development phase
90 participants
Enrollment target

Study Summary

The objective of the study is to evaluate the gingivitis control benefit of an established stannous fluoride containing toothpaste relative to a negative control dentifrice.

Primary Outcome

Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

Interventions

  • DRUG 0.454% stannous fluoride
  • DRUG 0.76% sodium monofluorophosphate
  • DRUG 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2020-10-19
Est. Completion 2020-11-20
Phase NA
Procter and Gamble

70 total trials

What the finished NCT05916508 record still lists

NCT05916508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 3 interventions - of which 0.454% stannous fluoride is the first listed.

NCT05916508 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05916508 about?

NCT05916508 is a clinical study titled "A Bleeding-Model Clinical Study". The objective of the study is to evaluate the gingivitis control benefit of an established stannous fluoride containing toothpaste relative to a negative control dentifrice.

What is the current status of trial NCT05916508?

This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2020-10-19. Estimated completion is 2020-11-20.

What interventions are being tested in trial NCT05916508?

The interventions under investigation include: 0.454% stannous fluoride (DRUG), 0.76% sodium monofluorophosphate (DRUG), 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM (DRUG).

Who is sponsoring clinical trial NCT05916508?

This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05916508's enrollment target sits among peer trials

90 941st of 2000 higher than 1,029 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05916508, the US trial registry maintained by the National Library of Medicine. NCT05916508 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.